Shire's ADHD Drug Vyvanse Fails to Meet Primary Endpoint in Phase III Studies

Published February 12, 2014

Shire's ADHD drug Vyvanse fails to meet primary endpoint in phase III studies
Filed under: dsm-iv-tr cocaine abuse
Shire's ADHD drug Vyvanse fails to meet primary endpoint in phase III studies. Ireland Saturday … Assess the risk of abuse prior to prescribing and monitor for signs of abuse and dependence while on therapy. Each of the two identically designed phase … Read more on pharmabiz.com